Abstract:Multiple endocrine neoplasia type 1 (MEN1) is a genetic syndrome in which patients develop neuroendocrine tumors (NETs), including pancreatic neuroendocrine tumors (PanNETs). The prolonged latency of tumor development in MEN1 patients suggests a likelihood that other mutations cooperate with Men1 to induce PanNETs. We propose that Pten loss combined with Men1 loss accelerates tumorigenesis. To test this, we developed two genetically engineered mouse models (GEMMs)—MPR (Men1flox/flox Ptenflox/flox RIP-Cre) and MPM (Men1flox/flox Ptenflox/flox MIP-Cre) using the Cre-LoxP system with insulin-specific biallelic inactivation of Men1 and Pten. Cre in the MPR mouse model was driven by the transgenic rat insulin 2 promoter while in the MPM mouse model was driven by the knock-in mouse insulin 1 promoter. Both mouse models developed well-differentiated (WD) G1/G2 PanNETs at a much shorter latency than Men1 or Pten single deletion alone and exhibited histopathology of human MEN1-like tumor. The MPR model, additionally, developed pituitary neuroendocrine tumors (PitNETs) in the same mouse at a much shorter latency than Men1 or Pten single deletion alone as well. Our data also demonstrate that Pten plays a role in NE tumorigenesis in pancreas and pituitary. Treatment with the mTOR inhibitor rapamycin delayed the growth of PanNETs in both MPR and MPM mice, as well as the growth of PitNETs, resulting in prolonged survival in MPR mice. Our MPR and MPM mouse models are the first to underscore the cooperative roles of Men1 and Pten in cancer, particularly neuroendocrine cancer. The early onset of WD PanNETs mimicking the human counterpart in MPR and MPM mice at 7 weeks provides an effective platform for evaluating therapeutic opportunities for NETs through targeting the MENIN-mediated and PI3K/AKT/mTOR signaling pathways.

Supplementary Figures 1-7 from Menin Epigenetically Represses Hedgehog Signaling in MEN1 Tumor Syndrome

Isolation, genomic organization, and expression analysis of Men1, the murine homolog of the MEN1 gene

Supplemetal Data from Genetic Ablation of Rbm38 Promotes Lymphomagenesis in the Context of Mutant P53 by Downregulating PTEN

Differentially expressed genes in Men1 knockout and wild‑type embryoid bodies for pancreatic islet development.

Conditional deletion of Men1 in the pancreatic β-cell leads to glucagon-expressing tumor development.

Functional Interaction Between Tumor Suppressor Menin And Activator Of S-Phase Kinase

Modeling MEN1 with Patient-Origin iPSCs Reveals GLP-1R Mediated Hypersecretion of Insulin

Menin in Cancer

Glucose-mediated Repression of Menin Promotes Pancreatic Β-Cell Proliferation.

Characterisation of Prostate Cancer Lesions in Heterozygous Men1 Mutant Mice

Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity

Data from MEN1 Degradation Induced by Neddylation and the CUL4B–DCAF7 Axis Promotes Pancreatic Neuroendocrine Tumor Progression

Supplementary Figure 3 from HIC1 Modulates Prostate Cancer Progression by Epigenetic Modification

Men1 Maintains Exocrine Pancreas Homeostasis in Response to Inflammation and Oncogenic Stress.

In vivo CRISPR screens identify a dual function of MEN1 in regulating tumor-microenvironment interactions

Two well-differentiated pancreatic neuroendocrine tumor mouse models

MEN1 mutations mediate clinical resistance to menin inhibition

MEN1 deficiency stabilizes PD‐L1 and promotes tumor immune evasion of lung cancer

Direct Binding of DNA by Tumor Suppressor Menin.

MEN1 is a regulator of alternative splicing and prevents R-loop-induced genome instability through suppression of RNA polymerase II elongation

Supplementary Figures 1-3, Tables 1-3, Table 7, Legends for Figures 1-3, Tables 1-7 from B-Raf Activation Cooperates with PTEN Loss to Drive C-Myc Expression in Advanced Prostate Cancer